MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1422535-52-1
MCE 国际站:T-3775440 hydrochloride
产品活性:T-3775440 (hydrochloride) 是一种赖氨酸特异性脱甲基酶1 (LSD1) 的不可逆性抑制剂,其 IC50 值为 2.1 nM。
研究领域:Epigenetics
作用靶点:Histone Demethylase
In Vitro: T-3775440 demonstrates irreversible inhibition of recombinant human LSD1, with a kinact/KI value of 1.7×105 (sec−1 M−1). T-3775440 is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nM). T-3775440 blocks the proliferation of several cell lines as quickly as day 3 of treatment. Notably, the granulocyte/macrophage markers CD86 and CD11b are commonly upregulated on both TF-1a and HEL92.1.7 cells in response to T-3775440 treatment, whereas the erythroid markers CD235a and CD71 are downregulated by this treatment. In CMK11-5 cells, CD86 mRNA expression is also clearly upregulated by T-3775440 in a concentration-dependent manner, although only a modest increase in cell surface CD86 expression is observed. T-3775440 treatment disrupts the LSD1-GFI1B association in a concentration-dependent manner. T-3775440 decreases LSD1 binding but not GFI1B binding and increases the level of dimethylated H3K4 at the PI16 locus.
In Vivo: T-3775440 upregulates CD86 mRNA expression in tumor xenografts of HEL92.1.7 cells in a dose-dependent manner following the oral administration of single doses ranging from 3 to 30 mg/kg. To investigate target engagement of this compound in tumors, PI16 expression levels is tested as a direct biomarker. As expected, PI16 suppression is dramatically reversed by T-3775440 treatment. In a TF-1a (AEL) tumor xenograft model, T-3775440 exhibits significant antitumor effects, with 15-day T/C values of 15.6% and <0% at doses of 20 and 40 mg/kg, respectively. T-3775440 also exhibits potent antitumor effects in an additional AEL model of HEL 92.1.7 and an AMKL model of CMK11-5, leading to nearly complete tumor growth suppression during the dosing period. It is found that in mice, T-3775440 treatment results in a transient reduction in platelets, followed by a significant rebound; this is considered a mechanism-based adverse effect of LSD1 inhibition. On a dosing schedule comprising 5 days on/2 days off, a statistically significant difference in body weight is observed between vehicle- and T-3775440–treated tumor xenograft model mice at higher doses. However, efficacious T-3775440 doses are tolerated in all subcutaneous tumor xenograft models.
相关产品:Covalent Screening Library Plus | Bioactive Compound Library Plus | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Covalent Screening Library | Anti-Cancer Metabolism Compound Library | Targeted Diversity Library | Heterocyclic Compound Library | Highly Selective Inhibitors Library | GSK-J4 | Eicosapentaenoic Acid | IOX1 | JIB-04 | CPI-455 | Iadademstat dihydrochloride | Tranylcypromine hemisulfate | KDM5-C70 | SP2509 | QC6352 | GSK2879552 | GSK-LSD1 dihydrochloride | Pulrodemstat benzenesulfonate | AS8351 | Seclidemstat | KDOAM-25 citrate | Daminozide | ML324 | NCGC00244536 | Corin | GSK467 | KDM5A-IN-1 | PFI-90 | KDM2A/7A-IN-1 | L-2-Hydroxyglutaric acid disodium | Procaine | SKLB325
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds